Literature DB >> 12553367

Skin necrosis following a recombinant interferon-beta-1b injection.

Chih-Hsun Yang1, Chien Hsun Chen, Heng-Leong Chan.   

Abstract

Recombinant interferon beta-1b (INF-beta-1b) has been proven to be an effective means of treating relapsing-remitting multiple sclerosis (MS). Adverse reactions to interferon therapy have been well documented. The most common side effects are transient influenza-like symptoms, including fever, fatigue, nausea, and myalgia. Cutaneous necrosis has occasionally been reported, mostly involving small and limited lesions. This article describes an MS patient who developed multiple large, deep cutaneous ulcers on INF-beta-1b injection sites, which subsequently required surgical treatment. Vessel thrombosis in the subcutaneous fatty layer and the clinical appearance of livedoid erythema beside the ulcers indicated that INF-3-1b may have caused skin necrosis through its vascular effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12553367

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  4 in total

1.  Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

Authors:  Antonie Giaever Beiske; Kjell-Morten Myhr
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

2.  Bilateral Skin Ulceration after Injection of Pegylated Interferon-alpha-2b in a Patient with Chronic Hepatitis C.

Authors:  L Gallelli; V Guadagnino; B Caroleo; N Marigliano; G B De Sarro; A Izzi
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 3.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

4.  Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review.

Authors:  Gita Faghihi; Akram Basiri; Mohsen Pourazizi; Bahareh Abtahi-Naeini; Ali Saffaei
Journal:  J Res Pharm Pract       Date:  2015 Apr-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.